Bot Image Receives FDA Clearance For Artificial Intelligence Software Used To Detect Prostate Cancer

Leveraging AI software for early and accurate detection can save lives, saving the patient and provider time and money.

FREMONT, CA: An important public health strategy is early diagnosis since it improves cancer outcomes. Early cancer diagnosis aims to detect symptomatic patients as early as possible so they can be treated successfully. Delayed or inaccessible cancer care reduces survival, increases treatment costs, and causes problems. AI-driven medical device CAD software is created by Omaha-based MRI medical device business Bot Image to significantly increase the accuracy and speed of prostate cancer detection (CADe) and diagnosis (CADx). The device, ProstatIDTM, combines conventional MRI scanning with artificial intelligence.

The capabilities of ProstatID go well beyond those of existing technologies, which have only helped segment a patient's prostate and improve prostate MRI cases' on-screen formatting rather than helping in lesion detection and cancer probability assignment.

"Prostate cancer screening and detection methods adoption has changed little over the past 30 years, despite the mountain of evidence pointing to the efficacy of superior technologies and the futility of the old methods. Sadly, this has resulted in the unnecessary and premature deaths of countless numbers of men in the US alone. ProstatID represents an exciting step in the fight to save lives." says Dr. Randall W. Jones, founder, and CEO of Bot Image.

The computer-aided design tool, now a Software-as-a-Service (SaaS) product, requires a secure VPN tunnel connection with the MRI system or radiology department server and the cloud-based ProstatID server. Both the software and connectivity must abide by HIPAA regulations and maintain data security.